Modern Retina Staff Reports

Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.

Mark Breazzano, MD, discusses the future of telehealth for retina specialists.

The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.

If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID-19.

The American Society of Cataract and Refractive Surgery hosted its 2021 ASCRS and ASOA Annual Meeting July 23-27 in Las Vegas, Nevada.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.

Mark Breazzano, MD, discusses the effects of the COVID-19 pandemic on daily practice for retina specialists.

A team of investigators found that the retina may offer signs of COVID-19 infection before symptoms present.

A poll for ophthalmologists and retina specialists to celebrate UV Safety Month. This poll will close July 28, 2021.

As the Fourth of July approaches, ophthalmologists warn patients to exercise caution with fireworks.

A survey of fireworks-related injuries for ophthalmologists and retina specialists.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

Standardization of Uveitis Nomenclature (SUN) Working Group utilized machine learning to create new uveitis classification criteria, inciting hope for implementation in clinical and research settings.

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

Members of the medical community gather virtually to discuss current issues in the field, public health, and general business.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

According to investigators at the Wilmer Eye Institute at the Johns Hopkins University School of Medicine conducting experiments in mouse tissues and human cells, by removing a membrane that lines the back of the eye they may be able improve the success rate for regrowing nerve cells damaged by blinding diseases.

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

According to an abstract presented during the 2020 Virtual Retina Society Annual Meeting, women are 34% less likely to receive a repair for a retinal detachment compared with men.

Thanks to researchers like Russell N. Van Gelder, MD, PhD, the possibility of restoring sight to people blinded by age-related macular degeneration or retinitis pigmentosa is another step closer to reality.

The University of California San Francisco brings its vision care and research facilities together at the UCSF Wayne and Gladys Valley Center for Vision.

The program is dedicated to the education of fellows and residents and offers a unique opportunity to share notable retina research with peers and mentors.

Euan S. Thomson, PhD, global president of ophthalmic devices at Carl Zeiss Meditec, talks about the “Zeiss Virtual Experience” during the 2020 EURETINA virtual meeting, and how attendees can navigate the booth to find the must-see products Zeiss is highlighting.

Lars Risby, international sales and training manager, Oculus Surgical, discusses how the global pandemic has re-prioritized production lines to enhance sterile product offerings and how the company is working with others in industry to improve overall product lines.